| [1]Hanahan D, Weinberg RA.Hallmarks of cancer: the next generation[J].Cell, 2011, 144(5):646-674[2]Varambally S, Dhanasekaran SM, Zhou M, et al.The polycomb group protein EZH2 is involved in progression of prostate cancer[J].Nature, 2002, 419(6907):624-629[3]Wang X, Hu B, Shen H, et al.Clinical and prognostic relevance of EZH2 in breast cancer: A meta-analysis[J].Biomed Pharmacother, 2015, 75:218-225[4]Jang SH, Lee JE, Oh MH, et al.High EZH2 Protein Expression Is Associated with Poor Overall Survival in Patients with Luminal A Breast Cancer[J].J Breast Cancer, 2016, 19(1):53-60[5]Takawa M, Masuda K, Kunizaki M, et al.Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker[J].Cancer Sci, 2011, 102(7):1298-1305[6]Mao L, Hong WK, Papadimitrakopoulou VA.Focus on head and neck cancer[J].Cancer Cell, 2004, 5(4):311-316[7]Cao W, Younis RH, Li J, et al.EZH2 promotes malignant phenotypes and is a predictor of oral cancer development in patients with oral leukoplakia[J].Cancer Prev Res, 2011, 4(11):1816-1824[8]Xie H, Peng C, Huang J, et al.Chronic Myelogenous Leukemia- Initiating Cells Require Polycomb Group Protein EZH2[J].Cancer Discov, 2016, 6(11):1237-1247[9]Chen J, Xu Y, Tao L, et al.MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2[J].Cell Physiol Biochem, 2017, 41(2):583-597[10]Gardner EE, Lok BH, Schneeberger VE, et al.Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis[J].Cancer Cell, 2017, 31(2):286-299[11]Zingg D, Debbache J, Schaefer SM, et al.The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors[J].Nat Commun, 2015, 6:6051-[12]Tiwari N, Tiwari VK, Waldmeier L, et al.Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming[J].Cancer Cell, 2013, 23(6):768-783[13]Karanikolas BD, Figueiredo ML, Wu L.Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines[J].Prostate, 2010, 70(6):675-688[14]Smits M, Nilsson J, Mir SE, et al.miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis[J].Oncotarget, 2010, 1(8):710-720[15]Zheng F, Liao YJ, Cai MY, et al.The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2[J].Gut, 2012, 61(2):278-289[16]Singh AK, Arya RK, Maheshwari S, et al.Tumor heterogeneity and cancer stem cell paradigm: updates in concept, controversies and clinical relevance[J].Int J Cancer, 2015, 136(9):1991-2000[17]Richly H, Aloia L, Di Croce L.Roles of the Polycomb group proteins in stem cells and cancer[J].Cell Death Dis, 2011, 2:e204-[18]Lund K, Adams PD, Copland M.EZH2 in normal and malignant hematopoiesis[J].Leukemia, 2014, 28(1):44-49[19]Chang CJ, Yang JY, Xia W, et al.EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling[J].Cancer Cell, 2011, 19(1):86-100[20]Tiffen J, Gallagher SJ, Hersey P.EZH2: an emerging role in melanoma biology and strategies for targeted therapy[J].Pigment Cell Melanoma Res, 2015, 28(1):21-30[21]van Vlerken LE, Kiefer CM, Morehouse C, et al.EZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional cancer stem cell reporter[J].Stem Cells Transl Med, 2013, 2(1):43-52[22]Rizzo S, Hersey JM, Mellor P, et al.Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2[J].Mol Cancer Ther, 2011, 10(2):325-335[23]Huang J, Zhou L, Chen H, et al.EZH2 is overexpressed in laryngeal squamous cell carcinoma and enhances the stem-like properties of AMC-HN-8 cells[J].Oncol Lett, 2016, 12(2):837-846[24]Miranda TB, Cortez CC, Yoo CB, et al.DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation[J].Mol Cancer Ther, 2009, 8(6):1579-1588[25]Suvà ML, Riggi N, Janiszewska M, et al.EZH2 is essential for glioblastoma cancer stem cell maintenance[J].Cancer Res, 2009, 69(24):9211-9218[26]Jiang X, Lim CZ, Li Z, et al.Functional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML)[J].PLoS One, 2015, 10(4):e0122983-[27]Knutson SK, Wigle TJ, Warholic NM, et al.A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells[J].Nat Chem Biol, 2012, 8(11):890-896[28]Knutson SK, Warholic NM, Wigle TJ, et al.Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2[J].Proc Natl Acad Sci U S A, 2013, 110(19):7922-7927[29]Campbell JE, Kuntz KW, Knutson SK, et al.EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity[J].ACS Med Chem Lett, 2015, 6(5):491-495[30]McCabe MT, Ott HM, Ganji G, et al.EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations[J].Nature, 2012, 492(7427):108-112[31]Verma SK, Tian X, LaFrance LV, et al.Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2[J].ACS Med Chem Lett, 2012, 3(12):1091-1096[32]Hua WF, Fu YS, Liao YJ, et al.Curcumin induces down-regulation of EZH2 expression through the MAPK pathway in MDA-MB-435 human breast cancer cells[J].Eur J Pharmacol, 2010, 637(1):16-21[33]Balasubramanian S, Chew YC, Eckert RL.Sulforaphane suppresses polycomb group protein level via a proteasome-dependent mechanism in skin cancer cells[J].Mol Pharmacol, 2011, 80(5):870-878[34]Wang X, Cao W, Zhang J, et al.A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination[J].EMBO J, 2017, 36(9):1243-1260 |
